01/20/21 7:50 AMNasdaq : BNTXPfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell CultureNew York and Mainz, Germany, January 20, 2021 -- Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralizeRHEA-AInegative
01/08/21 5:45 AMNasdaq : BNTXAn In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid TransmissionNew York and Mainz, Germany, January 8, 2021 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTechRHEA-AInegative
01/07/21 2:15 PMNasdaq : BNTXBioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in ScienceCollaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA vaccine encoding disease-related autoantigens that suppressed disease activity in several complex mouseRHEA-AIneutral
01/05/21 6:00 AMNasdaq : BNTXBioNTech to Present at the 39th Annual J.P. Morgan Healthcare ConferenceMAINZ, GERMANY, January 5, 2021 -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11,RHEA-AIneutral
12/29/20 1:11 PMNYSE, Nasdaq : PFE, BNTXPfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY(R)Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY (R), the companies' COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission's decision toRHEA-AIneutral
12/29/20 1:10 PMNasdaq : BNTXPfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY(R)European Union orders 100 million additional doses of COMIRNATY (R) bringing total doses to 300 million for 27 EU member states All 300 million doses expected to be delivered in 2020 and 2021 NEW YORK and MAINZ, GERMANY, December 29, 2020 -- Pfizer Inc. (NYSE: PFE) and BioNTech SERHEA-AIpositive
12/23/20 7:44 AMNasdaq : BNTXCorrection: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 VaccineU.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million All 200 million doses will be produced by U.S. manufacturing facilities and are expected to be delivered by July 31, 2021, allowing for 100 million people in theRHEA-AIneutral
12/23/20 7:02 AMNasdaq : BNTXPfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 VaccineU.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million All 200 million doses will be produced by U.S. manufacturing facilities and are expected tobe delivered by July 31, 2021, allowing for 100 million people in theRHEA-AIneutral
12/23/20 7:00 AMNYSE, Nasdaq : PFE, BNTXPfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 VaccinePfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies' COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered toRHEA-AIneutral
12/21/20 2:10 PMNasdaq : BNTXBioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development ProgramMainz, Germany, December 21, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will hold a press conference including a video webcast on Tuesday, December 22, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccineRHEA-AIneutral
